Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load

Internal Medicine

Volumn 49, Issue 11, 2010, Pages 957-963

  Arase, Yasuji ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Sezaki, Hitomi ^a   Suzuki, Yoshiyuki ^a   Kawamura, Yusuke ^a   Kobayashi, Masahiro ^a   Hosaka, Tetsuya ^a   Yatsuji, Hiromi ^a   Hirakawa, Miharu ^a   Saito, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; HCV genotype 1b; Natural interferon beta; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; NEUTROPENIA; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; COHORT STUDIES; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953345739     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3232     Document Type: Article

References (23)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
3. Hadziyannis SJ, Sette H, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
4. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069, 2002.
5. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 1015-1023, 2004.
6. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132: 103-112, 2007.
7. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 117: 408-413, 1999.
8. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43: 54-63, 2006.
9. Arase Y, Suzuki F, Suzuki Y, et al. Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern Med 46: 1827-1832, 2007.
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965, 2001.
11. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
12. Festi D, Sandri L, Mazzella G, et al. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 10: 12-16, 2004.
13. Kainuma M, Ogata N, Kogure T, et al. The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine 9: 365-372, 2002.
14. Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 25: 750-753, 1997.
15. Enomoto M, Tamori A, Kawada N, et al. Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomized pilot trial. Gut 55: 139-140, 2006.
16. Katamura Y, Suzuki F, Akuta N, et al. 2008. Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Intern Med 47: 1827-1834, 2008.
17. Doglio A, Laffont C, Caroli-Bosc FX, et al. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 137: 1567-1569, 1999.
18. Albadalejo J, Alonso R, Antinozzi R, et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36: 862-865, 1998.
19. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19: 13-18, 1994.
20. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645-652, 2003.
21. Arase Y, Suzuki F, Sezaki H, et al. Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intern Med 47: 1301-1307, 2008.
22. Arase Y, Suzuki F, Suzuki Y, et al. The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2. Intern Med 48: 1337-1342, 2009.
23. Arase Y, Suzuki F, Suzuki Y, et al. Virus clearance reduces the development of bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 82: 390-395, 2010.